A carregar...
Cost‐Effectiveness of Ivabradine for Heart Failure in the United States
BACKGROUND: Ivabradine is a heart rate–lowering agent approved to reduce the risk of hospitalization for worsening heart failure. This study assessed the cost‐effectiveness of adding ivabradine to background therapy in the United States from the perspective of a commercial or Medicare Advantage paye...
Na minha lista:
| Publicado no: | J Am Heart Assoc |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4889192/ https://ncbi.nlm.nih.gov/pubmed/27153871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.116.003221 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|